influenza
infect
continu
pose
seriou
problem
recent
outbreak
avian
influenza
huge
econom
effect
poultri
breed
sector
besid
econom
effect
human
health
stake
avian
influenza
also
infect
mammal
includ
human
increas
incid
resist
antivir
drug
major
concern
public
health
strain
tend
becom
aggress
adequ
therapeut
strategi
need
progress
made
identifi
sever
compound
aid
treatment
viral
infect
besid
treatment
human
use
farmer
protect
flock
howev
concern
aros
increas
incid
resist
antivir
drug
sever
caus
suggest
includ
inappropri
use
antivir
drug
treatment
human
outbreak
avian
influenza
sever
acut
respiratori
syndrom
sar
furthermor
shown
oseltamivir
carboxyl
fig
remov
degrad
normal
sewag
water
treatment
thu
enter
environ
waterfowl
posit
ingest
activ
oseltamivir
carboxyl
could
drive
select
resist
avian
influenza
strain
gut
especi
countri
eg
southeast
asia
waterfowl
human
come
close
contact
could
lead
spread
strain
incorpor
resist
gene
chang
host
final
amantadin
oseltamivir
arbidol
fig
allegedli
administ
poultri
livestock
china
southeast
asia
russia
prevent
excess
use
antivir
drug
food
drug
administr
fda
prohibit
nonconsist
use
two
type
antivir
drug
chicken
turkey
duck
amantadin
includ
amantadin
rimantadin
neuramidas
inhibitor
includ
zanamivir
oseltamivir
fig
abl
detect
extralabel
use
antivir
drug
analyt
method
need
detect
presenc
antivir
drug
poultri
muscl
also
abl
quantifi
concentr
present
confirm
ident
compound
present
level
low
reason
possibl
singleresidu
method
quantit
analysi
antivir
drug
biolog
matric
use
mass
spectrometri
publish
zanamivir
ribavirin
oseltamivir
includ
oseltamivir
carboxyl
oseltamivir
carboxyl
amandatin
includ
rimantadin
arbidol
recent
chan
et
al
report
multicompound
method
analysi
antivir
drug
poultri
muscl
use
zwitterion
hydrophil
interact
liquid
chromatographi
zichil
combin
mass
spectrometr
detect
howev
method
suitabl
screen
purpos
limit
analysi
basic
amphoter
antivir
drug
effici
control
antivir
drug
usag
quantit
confirmatori
multimethod
need
adequ
analysi
antivir
drug
appli
poultri
breed
includ
zanamivir
ribavirin
oseltamivir
includ
activ
metabolit
oseltamivir
carboxyl
amantadin
rimantadin
arbidol
main
difficulti
develop
multimethod
analysi
antivir
drug
broad
rang
physic
chemic
properti
antivir
drug
includ
extrem
polar
zanamivir
ribavirin
wherea
arbidol
reason
nonpolar
furthermor
select
includ
basic
amphoter
neutral
drug
paper
present
tandem
solidphas
extract
cleanup
combin
columnswitch
liquid
chromatographi
lc
system
quantit
confirmatori
analysi
broad
rang
antivir
drug
poultri
muscl
necess
use
tandem
spe
two
analyt
column
adequ
remov
matrix
effect
thu
enabl
quantit
analysi
antivir
drug
demonstr
method
fulli
valid
zanamivir
ribavirin
oseltamivir
oseltamivir
carboxyl
amantadin
rimantadin
arbidol
first
time
quantit
confirmatori
method
analysi
broad
rang
antivir
compound
present
hplc
grade
methanol
meoh
acetonitril
acn
obtain
biosolv
valkenswaard
netherland
formic
acid
fa
ammonia
solut
water
obtain
merck
darmstadt
germani
milliq
water
prepar
use
milliq
system
resist
least
millipor
billerica
usa
rimantadin
hcl
puriti
amantadin
hcl
puriti
obtain
sigmaaldrich
st
loui
mo
usa
arbidol
puriti
amplachem
carmel
usa
zanamivir
puriti
ribavirin
puriti
oseltamivir
phosphat
puriti
oseltamivir
carboxyl
puriti
intern
standard
phosphat
carboxyl
hcl
hcl
obtain
toronto
research
chemic
north
york
canada
stock
solut
oseltamivir
amantadin
rimantadin
correspond
isotop
label
intern
standard
arbidol
prepar
mg
meoh
stock
solut
zanamivir
ribavirin
oseltamivir
carboxyl
isotop
label
intern
standard
prepar
mg
water
dilut
stock
solut
prepar
fresh
daili
milliq
water
one
gram
poultri
tissu
transfer
polypropylen
pp
centrifug
tube
ml
meoh
ad
shake
use
vortex
mixer
subsequ
tube
shaken
min
rotari
tumbler
centrifug
g
min
upper
layer
isol
decant
pp
centrifug
tube
acidifi
ad
fa
prior
tandem
solidphas
extract
spe
procedur
fig
phenomenex
torranc
ca
usa
stratax
c
ml
strong
cation
exchang
spe
cartridg
condit
ml
vv
fa
meoh
ph
clean
pp
centrifug
tube
place
stratax
c
cartridg
acidifi
sampl
extract
follow
ml
meoh
ph
appli
onto
cartridg
total
breakthrough
collect
pp
centrifug
tube
fraction
addit
ammonia
fraction
centrifug
g
min
set
asid
stratax
c
cartridg
wash
ml
meoh
ph
clean
pp
centrifug
tube
place
spe
cartridg
antivir
compound
elut
cartridg
use
ml
vv
ammonia
meoh
ph
collect
pp
centrifug
tube
fraction
b
agil
technolog
santa
clara
ca
usa
bond
elut
phenylboron
acid
pba
ml
spe
cartridg
condit
ml
vv
fa
ph
follow
ml
meoh
ph
basifi
fraction
appli
onto
pba
cartridg
subsequ
wash
ml
meoh
ph
pp
centrifug
tube
contain
fraction
b
place
pba
cartridg
ribavirin
elut
cartridg
use
ml
meoh
ph
combin
fraction
b
solvent
combin
fraction
evapor
gentl
nitrogen
stream
dri
residu
redissolv
water
transfer
liquid
mass
spectrometri
autosampl
vial
schemat
present
columnswitch
system
present
electron
supplementari
materi
fig
lc
consist
acquiti
vacuum
degass
autosampl
binari
solvent
pump
water
milford
usa
lc
consist
separ
hendrikidoambacht
netherland
vacuum
degass
mix
chamber
two
type
hplc
pump
valv
separ
oper
lc
ms
mass
spectromet
quattro
premier
xe
water
milford
usa
water
symmetri
mm
analyt
column
column
thermo
fisher
scientif
waltham
usa
hypercarb
mm
analyt
column
initi
time
lc
run
gradient
solvent
mm
fa
water
solvent
b
mm
fa
acn
min
linear
increas
b
min
linear
increas
b
min
linear
decreas
b
min
equilibr
b
oper
flow
ml
lc
run
gradient
use
solvent
min
b
min
linear
increas
b
min
b
min
linear
decreas
b
min
equillibr
b
oper
flow
ml
inject
volum
inject
lc
phase
run
initi
time
min
column
place
seri
start
phase
min
switch
mobil
phase
lc
run
sole
symmetri
column
divert
wast
wherea
mobil
phase
lc
run
hypercarb
column
enter
ms
start
phase
min
switch
mobil
phase
lc
run
sole
symmetri
column
enter
ms
wherea
mobil
phase
run
hypercarb
column
divert
wast
detect
carri
use
mass
spectromet
posit
electrospray
ioniz
esi
mode
oper
paramet
capillari
voltag
kv
sourc
offset
v
cone
voltag
tabl
sourc
temperatur
desolv
temperatur
cone
ga
flow
l
desolv
ga
l
antivir
compound
fragment
use
collisioninduc
dissoci
select
reaction
monitor
srm
transit
given
tabl
data
acquir
process
use
masslynx
softwar
water
oseltamivir
use
intern
standard
intern
standard
arbidol
avail
method
develop
recoveri
matrix
effect
monitor
recoveri
calcul
divid
signal
blank
poultri
sampl
addit
compound
sampl
cleanup
matrixmatch
standard
mm
signal
blank
poultri
muscl
sampl
addit
equival
amount
compound
base
upon
recoveri
sampl
cleanup
matrixmatch
recoveri
standard
mmr
matrix
effect
calcul
divid
signal
mmr
signal
standard
solut
water
equival
concentr
matrix
effect
present
result
calcul
result
suppress
occur
result
signal
enhanc
occur
altern
columnswitch
setup
differ
singl
analyt
column
test
zichil
sequant
sweden
test
combin
gradient
elut
use
ammonium
format
water
acn
meoh
mobil
phase
ph
rang
reversedphas
rp
test
combin
gradient
elut
use
water
acn
meoh
mobil
phase
ph
rang
hypercarb
test
combin
gradient
elut
use
water
acn
meoh
tetrahydrofuran
mobil
phase
chromatograph
condit
matrix
effect
evalu
basi
spike
poultri
muscl
sampl
use
methanol
extract
combin
evapor
extract
solvent
redissolut
suitabl
solvent
aim
chromatograph
system
result
suffici
retent
compound
adequ
separ
antivir
drug
matrix
constitu
minim
matrix
effect
spe
use
strong
cation
exchang
pba
test
sampl
cleanup
spike
methanol
sampl
extract
acidifi
appli
onto
stratax
c
cartridg
breakthrough
applic
wash
collect
separ
eluent
analys
use
system
procedur
follow
pba
cartridg
spike
methanol
extract
basifi
prior
applic
full
valid
carri
accord
follow
paramet
determin
linear
trueness
repeat
withinlaboratori
reproduc
decis
limit
detect
capabl
select
robust
valid
carri
three
differ
occas
two
differ
technician
use
differ
batch
spe
cartridg
includ
differ
poultri
muscl
sampl
three
differ
day
matrixmatch
calibr
line
prepar
includ
follow
calibr
level
six
data
point
includ
zero
ad
solut
antivir
drug
blank
poultri
muscl
sampl
calibr
line
construct
plot
peak
area
normal
peak
area
intern
standard
versu
ad
concentr
carri
leastsquar
linear
regress
linear
consid
accept
coeffici
correl
least
day
seven
differ
blank
poultri
muscl
sampl
select
analys
spike
sampl
level
individu
antivir
drug
calcul
use
calibr
line
construct
day
trueness
calcul
level
divid
overal
averag
calcul
concentr
nomin
concentr
accord
trueness
select
valid
level
repeat
withinlab
reproduc
calcul
use
singl
factor
analysi
varianc
anova
accord
rel
withinlaboratori
reproduc
rsdrl
rel
repeat
rsdr
consid
accept
valu
calcul
horwitz
equat
two
third
valu
respect
ie
respect
valid
level
thompson
howev
demonstr
horwitz
equat
applic
lower
concentr
rang
suggest
complementari
model
basi
model
rsdrl
rsdr
accept
respect
latter
stringent
criteria
adopt
valid
studi
state
differ
poultri
muscl
sampl
use
within
day
repeat
pure
repeat
state
howev
use
differ
poultri
muscl
sampl
within
day
provid
better
understand
betweensampl
variat
valid
better
reflect
routin
analysi
situat
within
eu
regul
use
antivir
drug
food
product
establish
within
usa
fda
prohibit
extralabel
use
antivir
drug
therefor
confirm
ident
antivir
drug
carri
level
low
reason
possibl
therefor
decis
limit
calcul
basi
zero
toler
accord
assign
sampl
contain
antivir
drug
thu
deviat
blank
popul
calcul
basi
bandwidth
signal
blank
sampl
n
time
window
analyt
expect
detect
capabl
express
concentr
antivir
drug
poultri
muscl
sampl
found
noncompli
determin
basi
bandwidth
signal
blank
sampl
n
bandwidth
signal
sampl
spike
zanamivir
ribavirin
n
antivir
drug
n
time
window
analyt
expect
individu
blank
spike
sampl
analys
three
differ
occas
calcul
carri
suggest
antignac
et
al
without
normalis
base
signal
intern
standard
select
method
studi
basi
practic
theoret
studi
firstli
analys
blank
sampl
check
interfer
retent
time
correspond
antivir
drug
secondli
databas
search
compound
molecular
mass
equal
antivir
drug
could
possibl
present
poultri
muscl
sampl
standard
solut
add
tetrahydrogestrinon
thg
indic
possibl
interf
compound
analys
use
develop
method
result
chromatogram
check
interfer
retent
time
correspond
antivir
drug
robust
method
becam
clear
optimis
sampl
prepar
chromatograph
condit
ms
paramet
addit
minor
chang
method
test
duplic
extract
min
instead
dri
pba
cartridg
appli
vacuum
min
appli
extract
wash
cartridg
evapor
solvent
instead
trueness
repeat
result
compar
characterist
regular
method
suitabl
develop
method
test
appli
affect
sampl
materi
amantadineaffect
poultri
turkey
muscl
kind
gift
food
environment
research
agenc
fera
york
uk
determin
level
use
develop
method
compar
indic
amantadin
concentr
sampl
approxim
poultri
muscl
turkey
muscl
stationari
phase
use
three
differ
interact
mechan
test
obtain
suffici
separ
power
separ
antivir
drug
matrix
constitu
therefor
retent
factor
least
obtain
use
zichil
report
chan
et
al
screen
analysi
antivir
drug
howev
use
zichil
retent
obtain
arbidol
nonpolar
compound
studi
includ
screen
method
report
chan
et
al
slight
improv
retent
time
rt
made
proton
arbidol
pka
use
mobil
phase
ph
lower
ammonium
format
concentr
mm
nevertheless
insuffici
retent
obtain
arbidol
sever
matrix
effect
even
lateelut
polar
compound
like
zanamivir
ribavirin
observ
fig
use
rp
chromatographi
appli
column
zanamivir
elut
dead
time
system
slight
retent
obtain
ribavirin
retent
factor
although
matrix
effect
significantli
decreas
ribavirin
zanamivir
complet
suppress
matrix
constitu
fig
therefor
detect
even
concentr
poultri
muscl
use
hypercarb
stationari
phase
antivir
drug
includ
polar
compound
zanamivir
ribavirin
obtain
retent
retent
factor
respect
matrix
suppress
zanamivir
decreas
use
zichil
fig
result
detect
zanamivir
poultri
muscl
concentr
ribavirin
instead
signal
suppress
signal
enhanc
observ
signal
mmrssignal
standard
main
disadvantag
use
hypercarb
column
arbidol
nonpolar
compound
studi
elut
column
contain
free
phenyl
group
strongli
interact
column
materi
prevent
elut
even
use
tetrahydrofuran
mobil
phase
abl
analys
antivir
drug
within
one
run
columnswitch
system
combin
column
hypercarb
column
develop
schemat
lc
procedur
given
fig
zanamivir
ribavirin
hardli
retain
column
elut
within
min
subsequ
retain
hypercarb
column
hypercarb
column
zanamivir
ribavirin
separ
matrix
constitu
use
gradient
directli
detect
ms
meantim
antivir
compound
retain
column
elut
zanamivir
ribavirin
hypercarb
column
antivir
drug
elut
column
increas
organ
content
mobil
phase
pass
hypercarb
column
enter
ms
directli
total
run
time
includ
equilibr
column
min
present
fig
matrix
effect
use
columnswitch
lc
system
tremend
improv
zanamivir
reduc
matrix
effect
therefor
facilit
detect
confirm
concentr
least
poultri
muscl
addit
sampl
cleanup
prove
necessari
two
differ
spe
system
test
stratax
c
pba
rel
amount
antivir
drug
breakthrough
applic
sampl
extract
cartridg
breakthrough
wash
eluent
present
fig
b
ribavirin
remain
neutral
ph
interact
stratax
c
cartridg
elut
applic
extract
wash
procedur
antivir
compound
posit
charg
ph
therefor
retain
zanamivir
lowest
pka
antivir
compound
pka
show
breakthrough
wash
procedur
consid
accept
stratax
c
cartridg
consid
suitabl
cleanup
antivir
drug
includ
except
ribavirin
pba
materi
multipl
interact
mechan
strongest
coval
bind
high
ph
cisdiol
group
present
ribavirin
mechan
includ
van
der
waal
interact
bond
ionic
interact
therefor
result
use
type
materi
hard
predict
ribavirin
oseltamivir
amantadin
rimantadin
arbidol
retain
pba
cartridg
fig
zanamivir
oseltamivir
carboxyl
interact
pba
materi
elut
applic
extract
wash
procedur
stand
compound
contain
carboxyl
acid
moieti
left
unretain
pba
materi
explan
found
observ
result
conclud
combin
spe
materi
need
obtain
satisfactori
cleanup
antivir
drug
includ
studi
tandem
spe
procedur
develop
schemat
given
fig
compound
except
ribavirin
separ
matrix
constitu
retain
stratax
c
cartridg
breakthrough
cartridg
contain
ribavirin
basifi
centrifug
appli
onto
pba
cartridg
retain
ribavirin
order
separ
drug
matrix
constitu
well
eventu
eluent
cartridg
combin
solvent
evapor
final
residu
redissolv
water
matrix
effect
optimis
cleanup
procedur
determin
use
columnswitch
system
fig
recoveri
sampl
prepar
procedur
fig
determin
comparison
fig
fig
conclud
develop
sampl
cleanup
procedur
strongli
contribut
decreas
matrix
effect
compound
strike
decreas
suppress
zanamivir
sampl
cleanup
procedur
arbidol
signal
enhanc
approxim
observ
instead
signal
suppress
fig
conclud
appli
develop
sampl
cleanup
procedur
combin
rp
chromatographi
adequ
analysi
ribavirin
oseltamivir
oseltamivir
carboxyl
rimantadin
amantadin
arbidol
matrix
effect
zanamivir
still
pronounc
result
zanamivir
poultri
muscl
detect
use
sole
rp
chromatographi
use
combin
tandem
spe
sampl
cleanup
procedur
columnswitch
system
matrix
effect
suffici
decreas
enabl
detect
identif
antivir
drug
includ
relev
level
srm
chromatogram
blank
poultri
muscl
sampl
spike
zanamivir
ribavirin
present
fig
blank
poultri
muscl
spike
antivir
drug
present
fig
altern
use
columnswitch
setup
use
two
individu
inject
rp
hypercarb
column
test
sole
affect
result
zanamivir
ribavirin
rp
system
remain
columnswitch
system
matrix
effect
zanamivir
ribavirin
evalu
inject
clean
extract
hypercarb
column
found
observ
matrix
effect
zanamivir
use
inject
sole
hypercarb
column
increas
compar
columnswitch
setup
conclud
addit
matrix
interfer
remov
first
phase
column
switch
setup
advantag
analysi
zanamivir
ribavirin
statist
signific
differ
observ
thu
conclud
columnswitch
system
advantag
term
remov
matrix
effect
analysi
time
min
instead
min
therefor
use
columnswitch
system
prefer
overview
valid
result
present
tabl
zanamivir
ribavirin
oseltamivir
oseltamivir
carboxyl
amantadin
rimantadin
linear
rang
criterion
trueness
antivir
drug
well
within
establish
criterion
determin
maximum
rsdr
rsdrl
respect
thu
criteria
respect
therefor
valid
result
compli
establish
criteria
conclud
present
method
adequ
quantit
trace
analysi
six
antivir
drug
arbidol
inadequ
linear
trueness
repeat
withinlaboratori
reproduc
observ
two
valid
day
calibr
line
adequ
day
linear
insuffici
due
two
deviat
calibr
point
poor
trueness
repeat
withinlaboratori
reproduc
arbidol
caus
spike
sampl
show
quantit
result
time
higher
expect
like
caus
differ
matrix
interfer
play
major
role
arbidol
fig
effect
might
overcom
suitabl
intern
standard
arbidol
becom
avail
howev
present
method
suitabl
qualit
analysi
arbidol
oseltamivir
oseltamivir
carboxyl
amantadin
rimantadin
arbidol
calcul
decis
limit
vari
indic
antivir
drug
low
level
still
detect
calcul
detect
capabl
compound
sampl
spike
found
noncompli
base
upon
ion
ratio
criteria
case
n
indic
method
suitabl
confirmatori
analysi
antivir
drug
relev
level
zanamivir
ribavirin
calcul
valu
respect
indic
drug
relev
level
still
detect
calcul
detect
capabl
zanamivir
ribavirin
respect
even
though
calcul
zanamivir
exce
sampl
spike
zanamivir
ribavirin
found
noncompli
base
upon
ion
ratio
criteria
case
n
indic
calcul
least
zanamivir
slightli
overestim
method
suitabl
confirmatori
analysi
zanamivir
ribavirin
relev
level
well
theoret
studi
hydroxyflunixin
add
thg
found
molecular
mass
one
antivir
drug
might
theoret
interfer
describ
method
standard
solut
compound
prepar
inject
columnswitch
system
interf
signal
observ
chromatogram
furthermor
signific
interfer
detect
blank
sampl
n
therefor
procedur
consid
suffici
select
antivir
drug
method
develop
critic
step
identifi
firstli
ph
valu
solvent
use
spe
cleanup
procedur
critic
acid
methanol
ph
retain
zanamivir
stratax
c
materi
alkalin
meoh
least
ph
elut
amantadin
rimantadin
incorrect
ph
result
sever
decreas
recoveri
secondli
found
critic
centrifug
basifi
breakthrough
stratax
c
cartridg
appli
onto
pba
cartridg
prevent
clog
rugged
test
three
slight
deviat
procedur
might
occur
practic
specif
test
extract
min
instead
dri
pba
cartridg
appli
vacuum
min
appli
extract
wash
cartridg
evapor
solvent
instead
duplic
analys
incorpor
deviat
method
show
good
trueness
accept
duplic
indic
test
process
robust
two
amantadineaffect
muscl
sampl
analys
use
develop
method
result
poultri
muscl
turkey
muscl
sampl
level
good
agreement
indic
amantadin
concentr
approxim
poultri
muscl
turkey
muscl
conclud
develop
method
applic
real
muscl
sampl
method
use
tandem
spe
sampl
prepar
cleanup
combin
columnswitch
develop
analysi
seven
antivir
drug
poultri
muscl
rang
polar
reason
nonpolar
drug
includ
basic
amphoter
neutral
compound
remov
matrix
interfer
critic
detect
quantif
zanamivir
ribavirin
particular
neither
compound
suffici
retain
use
reversedphas
chromatographi
columnswitch
lc
system
combin
reversedphas
hypercarb
column
develop
system
show
improv
separ
power
rel
easi
setup
major
import
routin
situat
furthermor
tandem
spe
procedur
prove
mandatori
addit
remov
matrix
constitu
method
fulli
valid
accord
concentr
good
linear
trueness
repeat
withinlab
reproduc
obtain
zanamivir
ribavirin
oseltamivir
oseltamivir
carboxyl
amantadin
rimantadin
arbidol
paramat
compli
establish
criteria
method
result
sever
overestim
concentr
spike
sampl
select
robust
prove
suffici
appli
present
method
routin
situat
enabl
parallel
analysi
least
sampl
within
day
conclud
present
method
suitabl
quantit
confirmatori
analysi
zanamivir
ribavirin
level
low
oseltamivir
oseltamivir
carboxyl
amantadin
rimantadin
concentr
furthermor
present
method
suitabl
qualit
confirmatori
analysi
arbidol
concentr
